119425-91-1
Chemical Structure
Loureirin D
- CAS No.: 119425-91-1
- Formula:C16H16O5
- Molecular Weight:288.30
IUPAC Name: 3-(2,4-dihydroxy-6-methoxyphenyl)-1-(4-hydroxyphenyl)propan-1-one
InChIKey: AQMBVNGTZRFEPF-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C(O)C=C1)CCC2=C(OC)C=C(O)C=C2O
Biological Activity: Loureirin D is a selective P2Y12 receptor antagonist that penetrates the blood-brain barrier. Loureirin D inhibits the MAPK/JNK/ERK/p38 signaling pathway in microglia by acting on CD38, and inhibits ADP (HY-W010918)-induced platelet aggregation, MMP2/9-mediated tight junction disruption, and ischemia-related blood-brain barrier damage. Loureirin D protects endothelial cells from OGD-induced apoptosis. Loureirin D is used in studies of ischemic stroke and thrombosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Loureirin D | 99.30% | Loureirin D is a selective P2Y12 receptor antagonist that penetrates the blood-brain barrier. Loureirin D inhibits the MAPK/JNK/ERK/p38 signaling pathway in microglia by acting on CD38, and inhibits ADP (HY-W010918)-induced platelet aggregation, MMP2/9-mediated tight junction disruption, and ischemia-related blood-brain barrier damage. Loureirin D protects endothelial cells from OGD-induced apoptosis. Loureirin D is used in studies of ischemic stroke and thrombosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Peng J, et al. Loureirin D alleviates ischemia-induced blood-brain barrier disruption through CD38-mediated suppression of the microglial MAPK/JNK/ERK signaling pathway[J]. JNK/ERK signaling pathway.
- [2]. Peng J, et al. Bioactivity-Guided Fractionation of Dragon's Blood Phenolic Extracts Reveals Loureirin D as a P2Y12 Inhibitor Mediating Antiplatelet Effects. International journal of molecular sciences. 2025 Dec 26;27(1):282.
- [3]. Zhou Y, et al. Development and Validation of a UPLC-MS/MS for Determination of Loureirin D in Rat Plasma and Its Application to Pharmacokinetics. Biomedical chromatography : BMC. 2026 Aug;40(8):e70547.
